Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 96 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Insulin Hypoglycemia Clear all
Terminated Phase 2 Interventional Results available

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

NCT00798590
View directory record Official record
Conditions
Critically Ill, Hypoglycemia
Interventions
Glucagon-Like Peptide-1, Saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 10, 2026, 6:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of the Function of Hormones Present In Taste Buds

NCT00233298
View directory record Official record
Conditions
Diabetes, Obesity, Pre-Diabetes, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
12 Years to 50 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 10, 2026, 6:43 PM EDT
Terminated Phase 2Phase 3 Interventional

Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes

NCT00361907
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Effect of Pulsatile IV insulin on diabetic pt blood markers, Effect of Pulsatile IV Insulin on blood markers
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents

NCT02714972
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia, Hyperglycemia, Artificial Pancreas
Interventions
Hyperglycemia Minimization Algorithm
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years to 14 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy

NCT03234491
View directory record Official record
Conditions
Post-Prandial Hyperglycemia, Post-Prandial Hypoglycemia
Interventions
DiAS, Afrezza low dose, Afrezza high dose
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

NCT00797823
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin, Asp(B28)-, Glucagon, Placebo
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 10, 2026, 6:43 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

NCT04028960
View directory record Official record
Conditions
Type1diabetes
Interventions
Regular insulin (Humulin-R), intranasal route, SipNose intranasal device
Drug · Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 10, 2026, 6:43 PM EDT
Recruiting Not applicable Interventional

Safer Aging With Diabetes Monitoring

NCT06296485
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypoglycemia
Interventions
SAGE Group Sessions, Usual Care
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
75 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Fremont, California • Sacramento, California • San Jose, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 10, 2026, 6:43 PM EDT
Terminated Phase 1 Interventional Results available

Insulin Tolerance Test Study in Patients With Type 1 Diabetes

NCT04026750
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Pitolisant
Drug
Lead sponsor
High Point Clinical Trials Center
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Phase 4 Interventional

Continuous Subcutaneous Infusion of Pramlintide and Insulin

NCT00291772
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
13 Years to 22 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fasting on Insulin-induced Hypoglycemia Counterregulation in Healthy Humans

NCT04392843
View directory record Official record
Conditions
Hypoglycemia
Interventions
Fasting, Feeding
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 10, 2026, 6:43 PM EDT
Terminated Phase 2Phase 3 Interventional

Clinical Effects of Pulsatile Insulin Delivery on Cognitive Function- Phase 1

NCT00228865
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pulsatile IV insulin therapy, Effects of Pulsatile IV Insulin on Cognitive functions
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Not applicable Interventional Results available

Hybrid Closed Loop Insulin Delivery System in Hypoglycemia

NCT03215914
View directory record Official record
Conditions
Type1diabetes, Hypoglycemia Unawareness, Nocturnal Hypoglycemia, Hypoglycemia Night, Hypoglycemia
Interventions
MiniMed 670G system
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting

NCT01638299
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hypo-Hyper Minimizer (HHM) System
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Not applicable Interventional Results available

Point-of-Care Glucose Testing and Insulin Supplementation

NCT01702311
View directory record Official record
Conditions
Diabetes
Interventions
Bedtime insulin Aspart (Novolog)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 10, 2026, 6:43 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect Pulsatile IV Insulin Therapy on the Quality of Life in Patients With Types 1 and 2 Diabetes

NCT00228878
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Effects of Pulsatile IV insulin on Diabetic Quality of Life
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 10, 2026, 6:43 PM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus

NCT00287651
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Pulsatile IV Insulin, Effects of Pulsatile IV Insulin on Diabetic Retinopathy
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 10, 2026, 6:43 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

NCT00992901
View directory record Official record
Conditions
Post Bariatricsurgery, Hypoglycemia
Interventions
Exendin-(9-39), Atropine, GLP-1 and GIP
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-Loop Glucagon Administration For Hypoglycemia Treatment

NCT02181127
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Glucagon-only Bionic Pancreas
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Strategies to Improve Islet Survival

NCT00464555
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplant, Antithymocyte globulin, Basiliximab, Lisofylline, Sirolimus, Tacrolimus
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 10, 2026, 6:43 PM EDT
Active, not recruiting Phase 2 Interventional

Islet Cell Transplant for Type 1 Diabetes

NCT01909245
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Not applicable Interventional Results available

Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia

NCT00974051
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Terbutaline, 20% basal insulin reduction, Control
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03738865
View directory record Official record
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Novo Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Walnut Creek, California • Atlanta, Georgia • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 10, 2026, 6:43 PM EDT
Completed Not applicable Interventional Results available

Adjusting Insulin Delivery to Activity

NCT02299479
View directory record Official record
Conditions
Diabetes, Nocturnal Hypoglycemia
Interventions
Dexcom G4 Platinum CGM, Activity monitor
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 10, 2026, 6:43 PM EDT